Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors.

ESMO open·2026
Same author

ESMO adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Improved survival and rising incidence: insights from the largest retrospective study on leptomeningeal metastases in patients with NSCLC.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Gene expression profiling in a retrospective real-world cohort of breast cancer brain metastases and paired primary tumors identifies biological changes with potential therapeutic implications.

ESMO open·2025
Same author

Leptomeningeal metastasis from solid tumours: EANO-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

ESMO open·2023
Same author

Systemic relapses of primary CNS lymphomas (PCNSL): a LOC network study.

Annals of hematology·2023

Related Experiment Videos

Supportive care in neurooncology.

L Taillandier1, M Blonski, A Darlix

  • 1Unité de neurooncologie, service de neurologie, hôpital central, centre hospitalier universitaire, 29 avenue de Lattre-de-Tassigny, Nancy cedex, France. l.taillandier@chu-nancy.fr

Revue Neurologique
|September 10, 2011
PubMed
Summary

Brain tumor patients face altered quality of life due to tumors and treatments. This paper offers practical guidance on managing key symptoms like intracranial hypertension and end-of-life care.

Related Experiment Videos

Area of Science:

  • Neuro-oncology
  • Palliative Care
  • Clinical Symptom Management

Background:

  • Brain tumors significantly impact patient quality of life.
  • Comprehensive symptom management is crucial for brain tumor patients.
  • Existing management strategies require pragmatic optimization.

Purpose of the Study:

  • To provide a pragmatic approach to managing key symptoms in brain tumor patients.
  • To address intracranial hypertension, neurological deficits, and thromboembolism.
  • To guide care for confusion, epilepsy, and end-of-life symptoms.

Main Methods:

  • Review of current clinical practices for brain tumor symptom management.
  • Focus on pragmatic, actionable strategies for caregivers.
  • Integration of management for diverse symptoms, from neurological deficits to end-of-life care.

Main Results:

  • Optimized management of intracranial hypertension and neurological deficits.
  • Effective strategies for venous thromboembolism prevention and treatment.
  • Practical approaches to managing confusion, epilepsy, and end-of-life symptoms.

Conclusions:

  • A pragmatic, symptom-focused approach enhances brain tumor patient care.
  • Addressing a spectrum of symptoms improves overall quality of life.
  • Caregivers benefit from actionable guidance for complex symptom management.